VC Tally: $1.2bn Invested So Far In 2016 Includes Savara, Corvidia

New biotechnology companies still are able to raise some fairly large Series A venture capital rounds, contributing to a whopping $1.2bn in VC investment for drug developers during the first two months of 2016, but most startups and early-stage firms still are moving along at a pretty standard fundraising pace.